Showing results (61-70 of 72) with videos related to
Sort By:
Pageof 8
Archiv Der Pharmazie|September 3, 2025
Synthesis, Identification, and Characterization of a Novel 1,2,5-Selenadiazole Derivative as a Microtubule Targeting Agent That Overcomes Multidrug ResistanceFarhat Firdous, Syed Usama Bin Farrukh, Muhammad Furqan, et al.Cancer Research|July 24, 2015
Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug ResistanceMark D Gurden, Isaac M Westwood, Amir Faisal, et al.Bioorganic Chemistry|July 17, 2026
Synthesis, in vitro and in silico studies of transition metal complexes of chrysin with potent anticancer activity via GSK3β phosphorylation, modulation of p38 MAPK pathway and HDAC8 inhibitionMohammed Khaled Bin Break, Md Shahadat Hossan, Siddique Akber Ansari, et al.Journal of Medicinal Chemistry|November 8, 2013
Aurora isoform selectivity: design and synthesis of imidazo[4,5-b]pyridine derivatives as highly selective inhibitors of Aurora-A kinase in cellsVassilios Bavetsias, Amir Faisal, Simon Crumpler, et al.Journal of Medicinal Chemistry|October 10, 2012
Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemiaVassilios Bavetsias, Simon Crumpler, Chongbo Sun, et al.Blood Advances|April 14, 2020
Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736Andrew S Moore, Amir Faisal, Grace W Y Mak, et al.Journal of Medicinal Chemistry|June 23, 2010
Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidateVassilios Bavetsias, Jonathan M Large, Chongbo Sun, et al.Molecular Cancer Therapeutics|October 3, 2019
High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast CancersSimon J Anderhub, Grace Wing-Yan Mak, Mark D Gurden, et al.British Journal of Cancer|March 24, 2017
Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacyAmir Faisal, Grace W Y Mak, Mark D Gurden, et al.Journal of Medicinal Chemistry|September 11, 2018
Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4- d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N2-(2-Ethoxy-4-(4-methyl-4 H-1,2,4-triazol-3-yl)phenyl)-6-methyl- N8-neopentylpyrido[3,4- d]pyrimidine-2,8-diamine (BOS172722)Hannah L Woodward, Paolo Innocenti, Kwai-Ming J Cheung, et al.Pageof 8